Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Digestive System Diseases

Skin and Connective Tissue Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Blood and Lymph Conditions

Immune System Diseases

Heart and Blood Diseases

Rare Diseases

Uterine Cervical Neoplasms

Esophageal Neoplasms

Adenocarcinoma

Melanoma

Carcinoma, Non-Small-Cell Lung

Stomach Neoplasms

Lymphoma, Large B-Cell, Diffuse

Lung Neoplasms

Lymphoma

Multiple Myeloma

Neoplasms, Plasma Cell

Lymphoma, Non-Hodgkin

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Esophageal Cancer

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Stomach Cancer

Lymphosarcoma

Escalating doses of AB308 in combination with zimberelimab (360 mg) will be given every 3 weeks in participants with advanced malignancies.

Escalating doses of AB308 in combination with zimberelimab (480 mg) will be given every 4 weeks in participants with advanced malignancies.

Selected dose of AB308 in combination with zimberelimab will be given every 6 weeks in participants with advanced malignancies.

AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with in participants with locally advanced or metastatic NSCLC.

AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with melanoma.

AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with metastatic gastric, or gastroesophageal junction, or esophageal cancer.

AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with cervical cancer.

AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with hematological malignancies.

Administered intravenously (IV) as specified in the treatment arm

AB308

Administered IV as specified in the treatment arm

Zimberelimab

Medical Director

This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies

Arcus will provide access to individual de-identified participant data and related study documents (e.g., protocol, Statistical Analysis Plan \[SAP\], Clinical Study Report \[CSR\]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.

For more information, please visit our website.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies	NCT04772989	Advanced Solid ... Non Small Cell ... Melanoma Cervical Cancer Multiple Myelom... Lymphoma, Non-H... Diffuse Large B... Gastric Cancer Gastroesophagea... Esophageal Canc...	AB308 Zimberelimab	18 Years -	Arcus Biosciences, Inc.
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies	NCT04772989	Advanced Solid ... Non Small Cell ... Melanoma Cervical Cancer Multiple Myelom... Lymphoma, Non-H... Diffuse Large B... Gastric Cancer Gastroesophagea... Esophageal Canc...	AB308 Zimberelimab	18 Years -	Arcus Biosciences, Inc.
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies	NCT04772989	Advanced Solid ... Non Small Cell ... Melanoma Cervical Cancer Multiple Myelom... Lymphoma, Non-H... Diffuse Large B... Gastric Cancer Gastroesophagea... Esophageal Canc...	AB308 Zimberelimab	18 Years -	Arcus Biosciences, Inc.

Spots Global Cancer Trial Database for ab308

Every month we try and update this database with for ab308 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for ab308

Every month we try and update this database with for ab308 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for ab308 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.